ReCap Total Hip Resurfacing-Clinical Study

Explanation of the Study
This Food and Drug Administration (FDA) approved clinical trial will study the ReCap ® Total Hip Resurfacing System manufactured by Biomet, Inc.,Warsaw, Indiana. The study will evaluate the safety and effectiveness of the ReCap® Resurfacing System, a bone sparing alternative to traditional total hip replacement.

Unlike traditional total hip replacement where the entire hip joint is replaced, the ReCap ® Resurfacing System is designed to be more bone-sparing, replacing only the diseased or damaged surfaces of your hip joint.

As with a traditional total hip replacement, the ReCap® System includes two components: an acetabular and femoral component. The acetabular component (also called a cup or shell) is pressed into the cup shaped area of your pelvic bone. This component has a roughened surface (called PPS® titanium porous plasma spray), which promotes bone in-growth on the component surface.

The femoral component is placed into the top part of your thighbone (femur) and anchored by the use of bone cement. This femoral component has a central post, which is shorter than a traditional femoral stem. Both components have highly polished surfaces where they contact each other to re-create your "ball and socket" hip joint.

If you agree to participate in this FDA approved study, you will be asked to follow a routine post-operative physician office visit schedule. During each office visit the range of motion (movement) of your hip will be measured. You will be asked questions about your pain and ability to perform daily activities (such as walking, climbing stairs, putting on socks, etc.). X-rays (pictures) of your surgical hip will also be taken at each visit, which is standard following hip surgery. Your return for post-operative office visits is very important to the success of this clinical study.

Call 773-250-0500 to schedule an initial consultation with an NOHC Physician.